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A b s t r a c t  
A simple and sensitive high performance liquid chromatographic method is developed for the 
estimation of bosentan in pharmaceutical dosage forms. Chromatographic separation of the drug 
was achieved with an Thermo Scientific C18 column (250 mm ï 4.6 mm I.D., 5 μm particle size) 
analytical column using ammonium bicarbonate (pH was adjusted to 5.0 with phosphoric acid) and 
acetonitrile (70:30 v/v) as mobile phase. The instrumental settings are flow rate of 1.0 ml/min, 
column temperature at 25μ1ĈC, detector wavelength of 220 nm and the run time was 5 min. The 
retention time of the drug was 1.986 min. The developed method shows linearity over a range of 5-
100 μg/ml of bosentan with correlation coefficient of 0.9991. The relative standard deviation is less 
than 1.5%. The proposed method was found to be suitable and accurate for quantitative 
determination of bosentan in pharmaceutical dosage forms. 
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Introduction 
Pulmonary arterial hypertension (PAH) is a chronic, life-threatening 
disorder which severely hampers the function of the lungs and 
heart. In individuals with PAH, the levels of endothelin which is a 
potent endogenous vasoconstrictor is increased. Bosentan (BSN) 
[1-4] has been prescribed for the management of PAH. BSN is a 
vasodilator and oral dual endothelin receptor antagonist. BSN acts 
by competitively antagonizing the binding of endothelin to both 
endothelin receptors, ETA and ETB. Chemically, BSN is known as 
N-[6-(2-Hydroxyethoxy)-5-(2-methoxyphenoxy)-2-pyrimidin-2-yl-
pyrimidin-4-yl]-4-tert-butyl-benzenesulfonamide (Figure 1).  
 
 
Figure 1. Structure of bosentan 
 
Several analytical methods have been described in the literature 
for the determination of BSN in pharmaceutical dosage forms and 
biological fluids. UV-spectrophotometric methods [5-8] employing 
different solvents have been reported for the assay of BSN in 
pharmaceutical dosage forms.  These methods suffered from the 
lack of selectivity and sensitivity.  
Khan et al. [9] developed a stability indicating HPLC method for the 
determination of related substances of BSN. Jadhav et al. [10] 
proposed a stability indicating gradient reverse phase liquid 
chromatographic method for the determination of process and 
degradation impurities in BSN. The reported stability indicating 
methods are sensitive but suffered from disadvantages like having 
a narrow range of linear response, more retention time and lesser 
precision. Further more these methods are not applied to 
pharmaceutical dosage forms. 
Two narrow-bore liquid chromatography with ion spray tandem 
mass spectrometric detection methods (LC-MS) were reported by 
Lausecker et al. [11,12] The first method is applied for the 
determination of BSN in human plasma whereas the second 
method is useful for simultaneous determination of BSN and its 
three main metabolites in plasma, serum, bile, and liver samples 
from man, dog and rat.  The reported LC-MS methods require 
expensive detector, tedious sample preparation steps, require a 
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skilled person to operate the instrument. These features make 
them unattractive to routine analysis.  
There are few reports on the application of HPLC with UV detection 
[13-15] for the assay of BSN in bulk drug and pharmaceutical 
dosage forms. The disadvantages of the reported HPLC with UV 
detection methods are lack of sensitivity, lesser precision and 
having a narrow range of linear response. In addition, the retention 
time of the BSN is more which leads to a longer runtime for a 
single sample. 
The aim of the present study is to develop and validate a simple, 
fast, sensitive and precise HPLC with UV detection method for the 
assay of BSN in bulk and in pharmaceutical dosage forms.  
Materials and Methods  
Apparatus  
Chromatographic data were obtained using Shimadzu HPLC class 
VP series, (Shimadzu Corporation, Kyoto, Japan) isocratic high 
pressure liquid chromatographic system equipped with an LC-10 
AT pump, a variable wavelength programmable UV/Visible detector 
SPD-10A, a CTO-10 AS column oven, an SCL-10A system 
controller. The chromatographic system utilizes a Shimadzu class 
VP series version 5.03 computer program to control hardware, and 
to acquire and store data.  
Thermo Scientific C18 column (250 mm ï 4.6 mm I.D., 5 μm 
particle size, Phenomenex, Torrance, CA, USA) was used for the 
separation of BSN.  
Shimazdu (Tokyo, Japan) electronic weighing balance, model BL 
220 H was used for weighing the samples. 
Elico pH meter (Hyderabad, India) LI 120 model was used for pH 
measurements. 
Chemicals 
Milli-Q-water was used all the way through the process. It was 
obtained from Merck Specialties Private Ltd, Hyderabad, India. 
HPLC grade quality acetonitrile was purchased from Rankem 
laboratories, Mumbai, India.  HPLC grade quality orthophosphoric 
acid and ammonium bicarbonate were purchased from Merck, 
Mumbai, India. Bosentan reference standard was kindly supplied 
by MSN laboratories, Hyderabad. Bosentas tablets (Cipla Private 
Limited, Hyderabad, India), labeled to contain 62.5 and 125 mg 
bosentan per tablet, were purchased from commercial sources in 
the local pharmacy market. 
Mobile Phase 
The mobile phase is composed of a mixture of 20 mM ammonium 
bicarbonate (pH 5.0) and acetonitrile in the ratio of 70:30 (v/v). 
Ammonium bicarbonate (20 mM) was prepared by dissolving 0.158 
gm of ammonium bicarbonate in 100 ml of Milli-Q-water and the pH 
was adjusted to 5.0 with orthophosphoric acid. The mobile phase 
was filtered through a 0.45 μm membrane filter and degassed with 
a helium sparge for 15 min prior to use. 
Standard Drug Solutions 
The standard stock solution of BSN (1 mg/ml) was prepared in 
mobile phase.  The working standard solutions (5, 10, 20, 40, 60, 
80, 100 μg/ml) were prepared by appropriate dilution of the stock 
solution with mobile phase. 
Chromatographic Conditions 
Column   : Thermo Scientific C18 column 
Mode    : Reverse phase  
Mobile phase  :        20 mM Ammonium bicarbonate  
        (pH5.0): acetonitrile (70:30 v/v) 
Flow rate   :  1 ml/min 
Column temperature : 25μ1ĈC 
Injection volume  : 20 μl 
Detection wavelength : 220 nm 
Runtime    : 5 min  
Construction of the Calibration Graph  
Working standard solutions containing 5, 10, 20, 40, 60, 80, 100 
μg/ml of BSN were prepared by the dilution of standard stock BSN 
solution with the mobile phase. The mobile phase was pumped for 
about 30 minutes to saturate the column thereby to get the base 
line corrected. Twenty μL aliquot of each concentration was 
injected (triplicate) and eluted with the mobile phase under the 
chromatographic conditions described above. The average peak 
areas of BSN were plotted versus the final concentration of the 
BSN in μg/ml to get the calibration graph. Alternatively, the 
corresponding regression equation was derived. The concentration 
of the BSN was calculated either from the calibration graph or from 
the regression equation. 
Analysis of Bosentas tablets 
Ten Bosentas tablets were accurately weighed, finely crushed and 
thoroughly mixed. A quantity of the powder equivalent to 50 mg of 
BSN was transferred into a small conical flask and extracted with 
20 ml of mobile phase. The extract was filtered through 0.45 mm 
membrane filter into a 50 ml volumetric flask. The conical flask was 
washed with few ml of mobile phase and the washings were 
passed into the same volumetric flask and completed to the volume 
with the mobile phase. This solution was further diluted suitably 
with the same solvent to get 50 μg/ml of BSN. Twenty μL of the 
above solution was injected (triplicate) and eluted with the mobile 
phase under the chromatographic conditions described above. The 
nominal content of BSN in the tablets was computed either from 
the previously plotted calibration graph or from the regression 
equation. 
Results and Discussion 
Method Development 
In order to get the enhanced efficiency of the chromatographic 
system, the experimental conditions such as column, column 
temperature, mobile phase composition, pH of mobile phase and 
detection wavelength were optimized by varying one parameter at 
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a time and keeping the others constant. The results of optimization 
experiments have revealed that the Thermo Scientific C18 column 
(250 mm ï 4.6 mm I.D., 5 μm particle size) maintained at ambient 
temperature was suitable for the separation of BSN. Concerning 
the mobile phase, a mixture of 20 mM ammonium bicarbonate and 
acetonitrile was used. In order to get better separation and peak 
symmetry, the composition and pH of the mobile phase was varied 
until optimum composition and pH was selected. The best result 
was obtained by use of 70:30 (v/v) ratio of 20 mM ammonium 
bicarbonate and acetonitrile (pH 5.0 μ 0.05 adjusted with 
orthophosphoric acid). Isocratic elution at flow rate of 1.0 ml/min 
has been employed in the present study. Wavelength of 220 nm 
was selected for the UV detection. Under the optimum 
chromatographic conditions, the retention time obtained for BSN 
was 1.986 min. 
Method validation 
The proposed HPLC method was validated for parameters, such 
as system suitability, specificity, linearity, limit of detection (LOD), 
limit of quantification (LOQ), accuracy, precision and robustness, 
according to International Conference on Harmonization (ICH) 
guidelines [16]. 
The system suitability was studied by performing the experiment 
and looking for changes in retention time, peak area and peak 
asymmetry. Five injections of the standard solution of BSN (20 
μg/ml) were injected for this purpose. The system suitability was 
confirmed by calculating the relative standard deviation values for 
parameters like retention time, peak area, peak asymmetry, 
theoretical plates, plates per meter and height equivalent to 
theoretical plate.  It was observed that all the values are within the 
limits (Table 1). 
 
Table 1. System suitability parameters of bosentan 
Parameter Value* %RSD
Retention time (t) (Min) 1.986 0.25
Peak area 932524 0.10
Theoretical Plates (n) 4816 0.62
Plates per Meter (N) 19264 1.10
Height equivalent to theoretical 
plate(HETP) (mm) 
5.2 x 10-7 1.05
Peak asymmetry 0.98 1.02
* Average of five values 
  
The specificity study was carried out to confirm the absence of 
interference by the excipients in the tablet and components of 
mobile phase. Specificity of the proposed method is evaluated by 
comparing the chromatograms of tablet sample, blank mobile 
phase and standard BSN. It was observed that none of the peaks 
appears at the same retention time of BSN (Figures 2, 3 and 4). 
This confirmed the specificity of the method.  
 
Figure 2. Chromatogram of standard bosentan (40 μg/ml) 
 
 
Figure 3. Chromatogram of bosentan tablet sample (40 g/ml) 
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Figure 4. Chromatogram of blank mobile phase 
  
To detect the linearity of the proposed method, seven working 
standard solutions of BSN (5, 10, 20, 40, 60, 80, 100 μg/ml) were 
injected in to the column in triplicate. The chromatograms were 
recorded. Linearity was observed by plotting drug concentration 
against peak areas. BSN showed linear response in the 
concentration range of 5ă100 μg/ml. Linear regression analysis of 
the concentration-peak area data gave the following equation: 
 
Y = 47752x - 4217.1; R2 = 0.9991 
 
Where ÂxÊ is the concentration of BSN in μg/ml, ÂYÊ is the peak area 
and ÂR2Ê is the regression coefficient showing excellent linearity of 
the proposed method. 
In order to determine limit of detection (LOD) and limit of 
quantification (LOQ), concentration in the lower part of the linear 
range (5 μg/ml) of the calibration graph was used. A solution of 
BSN (5 μg/ml) was prepared and injected into the system (n=5). 
The standard deviation (SD) of responses was calculated. Limit of 
detection was calculated by (3.3 ï SD)/m and limit of quantification 
was calculated by (10 ï SD)/m, where „m‰ corresponds to the slope 
obtained in the linearity study. The calculated LOD and LOQ 
values were 0.225 and 0.684 μg/ml, respectively. This indicates 
the adequate sensitivity of the method. 
The precision and accuracy of the proposed method was 
determined by intra-day and inter-day analysis. Intra-day analysis 
was carried out by performing five repeated analysis of BSN at 
three different concentrations levels (5, 50 and 100 μg/ml) on the 
same day, under the same experimental conditions. The inter-day 
analysis of the method was assessed by carrying out the analysis 
for three consecutive days (inter-day). The results are given in 
Table 2. The standard deviation, relative standard deviation and 
recoveries obtained for the proposed method can be considered to 
be satisfactory.  
 
 
Table 2. Precision and accuracy of the proposed method 
Concentration of BSN (μg/ml) % Recovery % 
RSD Taken Found μ S.D* 
Intra-day analysis
5 4.98 μ 0.016 99.92 0.321
50 50.02 μ 0.121 100.06 0.241
100 99.94 μ 0.336 99.94 0.336
Inter-day analysis
5 4.97 μ 0.021 99.40 0.422
50 49.98 μ 0.161 99.96 0.322
100 100.06μ 0.428 100.06 0.427
* Average of five determinations  
 
The accuracy of the proposed method was also established by 
carrying out recovery experiments through standard addition 
technique.  For this purpose, pure BSN was spiked to the pre-
analyzed formulation. The total amount of BSN was once again 
found by the proposed method.  The recovery of the BSN was 
calculated. The results are presented in Table 3. The results 
showed that the common excipients present in tablets did not 
interfere in the assay of BSN by the proposed method. Thus the 
proposed method is very efficient for the assay of BSN. 
 
Table 3. Recovery study standard addition technique 
Label claim 
(mg/tablet) 
Pure BSN 
spiked (mg)  
Found (mg) 
μ S.D* 
Recovery 
(%) 
62.5 31.25 93.74 μ 0.842 99.89
125.0 62.50 187.48 μ1.808 99.96
* Average of three determinations  
 
The robustness of the proposed method was examined by 
deliberately changing chromatographic parameters such as mobile 
phase composition, flow rate, pH of the mobile phase and detection 
wavelength. For this study, three consecutive injections of BSN 
standard solutions (5 and 100 μg/ml) were applied. The results are 
summarized in Table 4. It is obvious from the results that none of 
these variables significantly affected the assay of BSN indicating 
that the proposed method could be considered as robust. 
 
   Table 4. Robustness of the proposed method 
Variable 
Concentration of BSN 
(μg/ml) 
% 
Recovery 
% 
RSD 
Taken Found μ S.D* 
Mobile phase 
(70:30 μ 2%) 
5 5.02 μ 0.020 100.40 0.398
100 99.96μ 0.141 99.96 0.141
pH of the mobile 
phase (5μ0.2)  
5 4.99 μ 0.033 99.80 0.661
100 99.78 μ 0.221 99.78 0.221
Flow rate 
(1 μ 0.1 ml/min) 
5 4.88 μ 0.015 97.60 0.307
100 99.76μ 0.321 99.76 0.321
Detection 
wavelength (220 μ 
1 nm)  
5 5.02 μ 0.029 100.04 0.577
100 99.66μ 0.161 99.66 0.161
* Average of three determinations  
Lavudu et al. International Journal of Drug Delivery 5 (2) 146-151 [2013] 
 
PAGE | 150 |
 
 
Application of the method to tablet dosage forms 
The proposed method was applied for the estimation of BSN in 
tablet dosage form. The results are shown in Table 5. The high 
recovery with low RSD value confirms the appropriateness of the 
proposed method for the routine analysis of BSN in tablet dosage 
forms. 
 
Table 5. Analysis of tablet dosage forms by the proposed method 
Tablet 
brand 
name 
Label claim 
(mg/tablet) 
Found (mg) 
 μ S.D* 
RSD 
(%)  
Recovery 
(%) 
Bosentas  62.50 61.49 μ 0.501 0.814 99.66
125.00 124.88μ0.998 0.799 99.96
* Average of three determinations  
 
Conclusion 
A reversed phase HPLC with UV detection method was developed 
for the determination of BSN in bulk and tablet dosage forms. The 
method was validated according to the International Conference on 
Harmonization guidelines. The method was found to be simple, 
economical, precise, accurate, specific, sensitive and robust. The 
features like short retention time (1.99 min), runtime (5 min), and 
flow rate (1 ml/min) make the method more attractive. These 
features help in decreasing the cost and time of analysis. The 
results of the analysis of tablet dosage forms are highly 
reproducible and are in good agreement with the label claim of the 
drug. The excipients generally present in the pharmaceutical 
formulations do not interfere in the assay of BSN. Hence, the 
developed method can be easily and conveniently adopted for 
routine analysis of BSN in quality control laboratories.  
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